Physician profile
Sharon S Pollock
NPI 1396825485
$3,787.21
in general payments reported to CMS, 2019-2025
30 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $19.22 · 2021: $50.39 · 2022: $48.89 · 2023: $1,050 · 2024: $995 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $470.20 | 2023-2025 | |
| Kaleo, INC. | $376.74 | 2019-2024 | Auvi-Q |
| Supernus Pharmaceuticals, INC. | $368.74 | 2023-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $293.20 | 2021-2025 | Vaxneuvance, Gardasil 9, Varivax |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250.00 | 2023 | |
| Collegium Pharmaceutical, INC. | $220.32 | 2025 | Jornay Pm |
| Tris Pharma INC | $177.83 | 2019-2023 | Quillichew Er, Dyanavel Xr, Quillivant |
| Glaxosmithkline, LLC. | $167.01 | 2019-2025 | Pediarix, Bexsero |
| Axsome Therapeutics, INC. | $134.55 | 2025 | Auvelity |
| Corium, LLC | $125.24 | 2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $122.07 | 2024 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $119.28 | 2024 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $117.69 | 2025 | |
| Novo Nordisk INC | $95.79 | 2024-2025 | Wegovy, Saxenda |
| Cranial Technologies, INC | $87.99 | 2021-2025 | Doc Band |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $76.88 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $75.32 | 2024-2025 | |
| Sanofi Pasteur INC. | $74.19 | 2019-2025 | |
| Abbott Laboratories | $72.97 | 2023-2025 | Id Now Instrument |
| Ars Pharmaceuticals Operations, INC. | $51.93 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $51.58 | 2023-2024 | Flumist Quadrivalent |
| Mayne Pharma Commercial LLC | $48.56 | 2023-2025 | |
| Noven Therapeutics, LLC | $46.80 | 2025 | Xelstrym |
| Verrica Pharmaceuticals INC. | $44.71 | 2024-2025 | Ycanth |
| Ironshore Pharmaceuticals INC. | $24.69 | 2019 | |
| Alk-Abello, INC | $22.56 | 2025 | Neffy |
| Hologic Sales and Service, LLC | $22.31 | 2023 | Aptima, Thinprep 2000 Processor |
| Rhythm Pharmaceuticals, INC. | $20.11 | 2023 | Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $14.38 | 2021 | |
| Mission Pharmacal Company | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.